Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Kim, Heungnam ^a   Gao, Wei ^a   Ho, Mitchell ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HYBRID PROTEIN; INTERLEUKIN 12; MESOTHELIN; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SS1(DSFV)PE38;

ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; MOUSE; NUDE MOUSE; PATHOLOGY; PROTEIN ENGINEERING; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-12; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, NUDE; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; TUMOR BURDEN;

EID: 84894100387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081919     Document Type: Article

References (45)

1. Chang K, Pastan I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 93: 136-140. doi:10.1073/pnas.93.1.136. PubMed: 8552591. (Pubitemid 26041483)
2. Chang K, Pastan I, Willingham MC (1992) Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50: 373-381. doi:10.1002/ijc.2910500308. PubMed: 1735605.
3. Ordóñez NG (2003) Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16: 192-197. doi: 10.1097/01.MP. 0000056981.16578.C3. PubMed: 12640097.
4. Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M et al. (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7: 3862-3868. PubMed: 11751476. (Pubitemid 34044602)
5. Hassan R, Kreitman RJ, Pastan I, Willingham MC (2005) Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13: 243-247. doi:10.1097/01.pai.00000141545.36485.d6. PubMed: 16082249. (Pubitemid 41209017)
6. Ho M, Bera TK, Willingham MC, Onda M, Hassan R et al. (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13: 1571-1575. doi:10.1158/1078-0432.CCR-06-2161. PubMed: 17332303. (Pubitemid 46450449)
7. Yu L, Feng M, Kim H, Phung Y, Kleiner DE et al. (2010) Mesothelin as a potential therapeutic target in human cholangiocarcinoma. J Cancer 1: 141-149. PubMed: 20922056.
8. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J et al. (2012) Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 133: 799-804. doi:10.1007/s10549-012-2018-4. PubMed: 22418702.
9. Hassan R, Ho M (2008) Mesothelin targeted cancer immunotherapy. Eur J Cancer;44: 46-53. doi:10.1016/j.ejca.2007.08.028. PubMed: 17945478. (Pubitemid 350262830)
10. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6: 559-565. doi:10.1038/nrc1891. PubMed: 16794638. (Pubitemid 43980544)
11. Chowdhury PS, Viner JL, Beers R, Pastan I (1998) Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNAimmunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 95: 669-674. doi:10.1073/pnas.95. 2.669. PubMed: 9435250. (Pubitemid 28083801)
12. Chowdhury PS, Pastan I (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 17: 568-572. doi:10.1038/9872. PubMed: 10385321. (Pubitemid 29262920)
13. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13: 5144-5149. (Pubitemid 47502082)
14. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15: 5274-5279. doi:10.1158/1078-0432.CCR-09-0062. PubMed: 19671873.
15. Yoon C, Johnston SC, Tang J, Stahl M, Tobin JF et al. (2000) Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12. EMBO J 19: 3530-3541. doi:10.1093/emboj/19.14.3530. PubMed: 10899108. (Pubitemid 30462112)
16. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA et al. (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697-1706. PubMed: 7913943. (Pubitemid 24251114)
17. Amsen D, Spilianakis CG, Flavell RA (2009) How are T(H)1 and T(H)2 effector cells made? Curr Opin Immunol 21: 153-160. doi:10.1016/j.coi.2009.03. 010. PubMed: 19375293.
18. Car BD, Eng VM, Lipman JM, Anderson TD (1999) The toxicology of interleukin-12: a review. Toxicol Pathol 27: 58-63. doi: 10.1177/ 019262339902700112. PubMed: 10367675. (Pubitemid 29075746)
19. Halin C, Gafner V, Villani ME, Borsi L, Berndt A et al. (2003) Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 63: 3202-3210. PubMed: 12810649. (Pubitemid 36735873)
20. Gafner V, Trachsel E, Neri D (2006) An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 119: 2205-2212. doi:10.1002/ijc.22101. PubMed: 16823838. (Pubitemid 44423682)
21. Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D (2012) The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 18: 4092-4103. doi:10.1158/1078-0432.CCR-12-0282. PubMed: 22693354.
22. Ho M, Hassan R, Zhang J, Wang QC, Onda M et al. (2005) Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 11: 3814-3820. doi:10.1158/1078-0432.CCR-04-2304. PubMed: 15897581. (Pubitemid 40685601)
23. Feng M, Zhang J, Anver M, Hassan R, Ho M (2011) In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice. J Cancer 2: 123-131. PubMed: 21479131.
24. Tagawa M (2000) Cytokine therapy for cancer. Curr Pharm Des 6: 681-699. doi:10.2174/1381612003400597. PubMed: 10788604.
25. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR et al. (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688-696. PubMed: 7884429.
26. Eggermont AM, Schraffordt KH, Liénard D, Kroon BB, van Geel AN et al. (1996) Isolated limb perfusion with high-dose tumor necrosis factoralpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-2665. PubMed: 8874324. (Pubitemid 26329649)
27. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G et al. (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548. PubMed: 9326219. (Pubitemid 27413462)
28. Geldhof AB, Moser M, Lespagnard L, Thielemans K, De BP (1998) Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91: 196-206. PubMed: 9414285. (Pubitemid 28018745)
29. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E et al. (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177: 1199-1204. doi:10.1084/jem.177.4.1199. PubMed: 8096238. (Pubitemid 23097410)
30. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R (1992) Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 143: 127-142. doi:10.1016/0008-8749(92)90011-D. PubMed: 1352483.
31. Colombo MP, Trinchieri G (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168. doi:10.1016/S1359- 6101(01)00032-6. PubMed: 11900991. (Pubitemid 34229390)
32. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B et al. (1998) Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol 19: 738-746. doi:10.1165/ajrcmb.19.5. 3257m. PubMed: 9806738. (Pubitemid 128353673)
33. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR et al. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223-1230. doi:10.1084/jem.178.4.1223. PubMed: 8104230. (Pubitemid 23277355)
34. Trinchieri G (1997) Function and clinical use of interleukin-12. Curr Opin Hematol 4: 59-66. doi:10.1097/00062752-199704010-00010. PubMed: 9050381.
35. Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA (1997) IL-12 induces T helper 1-directed antitumor response. J Immunol 158: 3359-3365. PubMed: 9120294. (Pubitemid 127484054)
36. Rodolfo M, Colombo MP (1999) Interleukin-12 as an adjuvant for cancer immunotherapy. Methods 19: 114-120. doi:10.1006/meth.1999.0836. PubMed: 10525447. (Pubitemid 29497761)
37. Siddiqui F, Li CY, Larue SM, Poulson JM, Avery PR et al. (2007) A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol Cancer Ther 6: 380-389. doi:10.1158/1535-7163.MCT-06-0342. PubMed: 17237297.
38. Ling P, Gately MK, Gubler U, Stern AS, Lin P et al. (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154: 116-127. PubMed: 7527811.
39. Heuser C, Diehl V, Abken H, Hombach A (2003) Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells. Int J Cancer 106: 545-552. doi:10.1002/ijc.11279. PubMed: 12845650. (Pubitemid 36966211)
40. Helguera G, Rodríguez JA, Penichet ML (2006) Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol Cancer Ther 5: 1029-1040. doi:10.1158/1535-7163.MCT-05-0488. PubMed: 16648575. (Pubitemid 43724604)
41. Lo KM, Lan Y, Lauder S, Zhang J, Brunkhorst B et al. (2007) huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models. Cancer Immunol Immunother 56: 447-457. doi:10.1007/s00262-006-0203-1. PubMed: 16874486. (Pubitemid 46204531)
42. Sommavilla R, Pasche N, Trachsel E, Giovannoni L, Roesli C et al. (2010) Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12. Protein Eng Des Sel 23: 653-661. doi:10.1093/protein/gzq038. PubMed: 20551083.
43. Feng Y, Xiao X, Zhu Z, Streaker E, Ho M et al. (2009) A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther 8: 1113-1118. doi:10.1158/1535-7163.MCT-08-0945. PubMed: 19417159.
44. Ho M, Feng M, Fisher RJ, Rader C, Pastan I (2011) A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer. 128: 2020-2030. doi:10.1002/ijc.25557. PubMed: 20635390.
45. Tang Z, Feng M, Gao W, Phung Y, Chen W et al. (2013) A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther 12: 416-426. doi:10.1158/1535-7163.MCT-12-0731. PubMed: 23371858.